These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 8788441

  • 21. The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle.
    Lodge NJ, Smith MA.
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):444-51. PubMed ID: 8897447
    [Abstract] [Full Text] [Related]

  • 22. Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts.
    Jung YS, Moon CH, Cho TS, Yoo SE, Shin HS.
    Jpn J Pharmacol; 1998 Jan; 76(1):65-73. PubMed ID: 9517406
    [Abstract] [Full Text] [Related]

  • 23. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.
    Grover GJ, Newburger J, Sleph PG, Dzwonczyk S, Taylor SC, Ahmed SZ, Atwal KS.
    J Pharmacol Exp Ther; 1991 Apr; 257(1):156-62. PubMed ID: 2019983
    [Abstract] [Full Text] [Related]

  • 24. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration.
    Grover GJ, D'Alonzo AJ, Parham CS, Darbenzio RB.
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):145-52. PubMed ID: 7564356
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.
    D'Alonzo AJ, Darbenzio RB, Hess TA, Sewter JC, Sleph PG, Grover GJ.
    Cardiovasc Res; 1994 Jun; 28(6):881-7. PubMed ID: 7923295
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution.
    Grover GJ, Sleph PG.
    J Cardiovasc Pharmacol; 1995 Nov; 26(5):698-706. PubMed ID: 8637183
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pharmacological characterization of vasorelaxant effects of BMS-180448, a novel cardioselective ATP-sensitive potassium channel opener, in rat aorta.
    Park YS, Yoo SE, Shin HS, Jin YR, Yun YP.
    J Pharmacol Sci; 2003 Jul; 92(3):218-27. PubMed ID: 12890887
    [Abstract] [Full Text] [Related]

  • 32. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
    Quast U, Cook NS.
    J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo.
    Toombs CF, Norman NR, Groppi VE, Lee KS, Gadwood RC, Shebuski RJ.
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1261-8. PubMed ID: 1469632
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Electrophysiologic and arrhythmogenic effects of the potassium channel agonist BRL 38227 in anesthetized dogs.
    de La Coussaye JE, Eledjam JJ, Bruelle P, Peray PA, Bassoul BP, Gagnol JP, Sassine A.
    J Cardiovasc Pharmacol; 1993 Nov; 22(5):722-30. PubMed ID: 7506325
    [Abstract] [Full Text] [Related]

  • 38. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
    Katz LB, Giardino EC, Salata JJ, Moore JB, Falotico R.
    J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
    [Abstract] [Full Text] [Related]

  • 39. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
    Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG.
    J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.